- Home
- AVD vs OBIO Comparison
AVD vs OBIO Comparison
Compare AVD & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVD
- OBIO
- Stock Information
- Founded
- AVD 1969
- OBIO 2017
- Country
- AVD United States
- OBIO United States
- Employees
- AVD N/A
- OBIO N/A
- Industry
- AVD Agricultural Chemicals
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- AVD Industrials
- OBIO Health Care
- Exchange
- AVD Nasdaq
- OBIO Nasdaq
- Market Cap
- AVD 165.8M
- OBIO 156.6M
- IPO Year
- AVD N/A
- OBIO N/A
- Fundamental
- Price
- AVD $5.21
- OBIO $5.17
- Analyst Decision
- AVD Strong Buy
- OBIO Strong Buy
- Analyst Count
- AVD 3
- OBIO 5
- Target Price
- AVD $16.67
- OBIO $15.80
- AVG Volume (30 Days)
- AVD 357.2K
- OBIO 182.8K
- Earning Date
- AVD 03-13-2025
- OBIO 11-12-2024
- Dividend Yield
- AVD 1.16%
- OBIO N/A
- EPS Growth
- AVD N/A
- OBIO N/A
- EPS
- AVD N/A
- OBIO N/A
- Revenue
- AVD $553,839,000.00
- OBIO $2,647,000.00
- Revenue This Year
- AVD N/A
- OBIO $22.61
- Revenue Next Year
- AVD $5.98
- OBIO $16.64
- P/E Ratio
- AVD N/A
- OBIO N/A
- Revenue Growth
- AVD N/A
- OBIO N/A
- 52 Week Low
- AVD $4.26
- OBIO $3.96
- 52 Week High
- AVD $14.28
- OBIO $9.65
- Technical
- Relative Strength Index (RSI)
- AVD 58.04
- OBIO 48.86
- Support Level
- AVD $4.46
- OBIO $5.00
- Resistance Level
- AVD $5.01
- OBIO $5.70
- Average True Range (ATR)
- AVD 0.24
- OBIO 0.57
- MACD
- AVD 0.10
- OBIO 0.03
- Stochastic Oscillator
- AVD 93.97
- OBIO 51.71
About AVD American Vanguard Corporation ($0.10 Par Value)
American Vanguard Corp is a United States-based diversified specialty and agricultural products company. It manufactures and formulates chemicals for crops, turf and ornamental plants, and human and animal health protection. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.